Enzalutamide reduces skeletal-related events in men with advanced castration-resistant prostate cancer
the ONA take:
According to a new study published in the journal Lancet Oncology, enzalutamide was found to decrease the risk of skeletal-related events, including radiotherapy to the bone and spinal cord compression, in men with metastatic castration-resistant prostate cancer (mCRPC). In addition, enzalutamide lowered pain and increased quality of life.
In the phase 3 AFFIRM study, patients with mCRPC whose disease progressed on or after docetaxel either took enzalutamide, an androgen receptor, by mouth once daily or placebo. Researchers found that enzalutamide decreased the risk of skeletal-related events by 31% compared with placebo (P=0.0001), and the duration to first skeletal-related event was 16.7 months for patients who took enzalutamide versus 13.3 months for those who took placebo (P=0.0001).
Furthermore, enzalutamide decreased pain severity (P<0.0001) and risk of pain progression (P=0.0018). Patients on enzalutamide experienced health-related quality of life (HRQoL) deterioration after 9.0 months, while those on placebo had HRQoL deterioration in 3.7 months (P<0.0001).
Xtandi (enzalutamide) was initially approved by the U.S. Food and Drug Administration (FDA) in 2012, and the FDA recently approved enzalutamide as first-line therapy for men with mCRPC.
Enzalutamide was found to decrease the risk of skeletal-related events in mCRPC.
Enzalutamide (XTANDI™) reduces the risk of skeletal-related events compared with placebo, as well as reducing pain and increasing quality of life in men with metastatic castration-resistant prostate cancer (mCRPC) according to new results from the AFFIRM study published in Lancet Oncology.
Bone is the most common site of spread in prostate cancer, accounting for about 90% of metastases, resulting in some of the most painful and functionally compromising complications of the disease.
Professor Johann De Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research London, and Head of the Drug Development Unit at The Royal Marsden NHS Foundation Trust, comments: "These quality of life data endorse the fact that enzalutamide is a major advance in the treatment of prostate cancer."
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Exercise May Mitigate Doxorubicin-related Cardiotoxicity
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
- Exercise May Mitigate Cardiotoxicity Associated With Doxorubicin Treatment
- Mobile Health Apps Becoming More Popular Among Patients and Clinicians
- Online Learning Modules Improve Exercise Counseling, But Not Participation
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|